Second external investment in life sciences solidifies previously announced strategy to utilize significant cash position to create additional stockholder value LAS VEGAS / May 21, 2024 / Business Wire / PharmaCyte Biotech, Inc. (Nasdaq: PMCB) (“PharmaCyte” or the “Company”), today announced a $7 million investment in MyMD Pharmaceuticals, Inc. (Nasdaq:MYMD) (“MyMD”) a clinical stage biopharmaceutical company committed to... Read More

New investment marks expansion of corporate strategy to utilize significant cash position to create additional shareholder value LAS VEGAS / Nov 15, 2023 / Business Wire / PharmaCyte Biotech, Inc. (Nasdaq: PMCB) (“PharmaCyte” or the “Company”) announces it has made a $5 million investment in Femasys, Inc. (Nasdaq:FEMY) (“Femasys”), a biomedical company focused on meeting significant unmet needs for women worldwide. Femasys... Read More

Company prepares for comprehensive discussion with FDA to determine appropriate next steps for technology while evaluating additional opportunities LAS VEGAS / Oct 31, 2023 / Business Wire / PharmaCyte Biotech, Inc. (Nasdaq: PMCB) (“PharmaCyte” or the “Company”) provides an update on its investigation of its Cell-in-a-Box technology and initial next steps in development. Following a comprehensive scientific review of amassed... Read More

LAS VEGAS / Jun 15, 2023 / Business Wire / PharmaCyte Biotech, Inc. (Nasdaq: PMCB) (“PharmaCyte” or the “Company”) today announces the final results of its previously announced tender offer to acquire up to 7,750,000 million shares of the Company’s common stock, par value $0.001 per share, at a price of $3.25 per share in cash, less any applicable withholding taxes and without interest. The tender offer expired one minute... Read More

Concurrently, the Company Announces $35 Million Financing of Convertible Preferred Stock at $4.00 per Share LAS VEGAS / May 11, 2023 / Business Wire / PharmaCyte Biotech, Inc. (Nasdaq: PMCB) (“PharmaCyte” or the “Company”) today announces a cash tender offer for up to 7,750,000 shares at $3.25 per share, less any applicable withholding taxes and without interest. The Company also announces that it has completed a private... Read More

LAS VEGAS / Feb 02, 2023 / Business Wire / PharmaCyte Biotech, Inc. (Nasdaq:PMCB) (“PharmaCyte” or the “Company”), a biotechnology company focused on evaluating its signature live-cell encapsulation technology, Cell-in-a-Box ® for potential development of cellular therapies for cancer, diabetes and malignant ascites, announced today that its Board of Directors has authorized a second share repurchase program to repurchase up... Read More